Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 5:42:101409.
doi: 10.1016/j.conctc.2024.101409. eCollection 2024 Dec.

Clinical study of Jianpi Qingchang decoction in the treatment of ulcerative colitis patients with spleen deficiency and dampness-heat syndrome accompanied by fatigue: Study protocol for a randomized controlled trial

Zi-Xuan Liu  1 , Xiao-Yan Liu  1 , Wei-Wei Tan  1 , Wei-Bing Zhang  1 , Ya-Li Zhang  2 , Lie Zheng  3 , Yan-Cheng Dai  1
Affiliations

Clinical study of Jianpi Qingchang decoction in the treatment of ulcerative colitis patients with spleen deficiency and dampness-heat syndrome accompanied by fatigue: Study protocol for a randomized controlled trial

Zi-Xuan Liu et al. Contemp Clin Trials Commun. .

Abstract

Background: Ulcerative colitis (UC) is a chronic non-specific inflammatory intestinal disease, categoried under "dysentery" and "intestinal bleeding" in Traditional Chinese Medicine (TCM). Jianpi Qingchang decoction (JPQC) is a combination formula specifically designed for the treatment of UC. The primary objective of this study is to examine the clinical efficacy of JPQC in individuals diagnosed with UC who exhibit both spleen deficiency and dampness-heat syndrome, along with the presence of fatigue. The investigation will focus on assessing the impact of JPQC on the gut microbiota and metabolites in these patients, aiming to elucidate the regulatory mechanism that JPQC exerts on the gut microbiota and metabolites in the context of UC-related fatigue.

Methods: In this randomized clinical trial, 140 subjects diagnosed with UC will be recruited and randomized into two groups. They will receive either JPQC combined with mesalazine or mesalazine alone for 12 weeks. Follow-up visits will be conducted every four weeks, with a post-treatment visit scheduled at 6 months. The primary outcome measures include the Inflammatory bowel disease fatigue scale(IBD-F). Secondary efficacy indicators comprise the assessment of TCM syndrome and individual syndrome efficacy before and after treatment, Modified Mayo score, Simple clinical colitis activity index (SCCAI), as well as the Inflammatory Bowel Disease Questionnaire (IBDQ) for each group. The other outcomes are the Intestinal microbial diversity and non-targeted metabonomics, which will be measured at baseline and 12 weeks after randomization.

Discussion: If effective, JPQC will provide substantial clinical evidence concerning the effectiveness and safety in the treatment of patients with UC experiencing spleen deficiency and dampness-heat syndrome accompanied by fatigue.

Trial registration: ChiCTR2300068348.

Keywords: Fatigue; Jianpi Qingchang decoction; Randomized controlled trial; Spleen deficiency and dampness-heat syndrome; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The flow chart of the trial.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Le Berre C., Honap S., Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571–584. doi: 10.1016/S0140-6736(23)00966-2. - DOI - PubMed
    1. Pekow J. Fatigue in inflammatory bowel disease: a common complaint with few answers. Gastroenterology. 2022;163:1164–1165. doi: 10.1053/j.gastro.2022.08.050. - DOI - PubMed
    1. Gramont B., Goutte J., Feasson L., Millet G., Hupin D., Cathebras P. [Chronic fatigue: what investigations? And what for?] Rev. Med. Interne. 2023;44:662–669. doi: 10.1016/j.revmed.2023.05.007. - DOI - PubMed
    1. Keefer L., Bedell A., Norton C., Hart A.L. How should pain, fatigue, and emotional wellness be incorporated into treatment goals for optimal management of inflammatory bowel disease? Gastroenterology. 2022;162:1439–1451. doi: 10.1053/j.gastro.2021.08.060. - DOI - PubMed
    1. Mcging J.J., Radford S.J., Francis S.T., Serres S., Greenhaff P.L., Moran G.W. Review article: the aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies. Aliment. Pharmacol. Ther. 2021;54:368–387. doi: 10.1111/apt.16465. - DOI - PubMed

LinkOut - more resources